Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"

Stephanie R. Earnshaw; Cheryl L. McDade; Michele R. Wilson; Raymond A. Farkouh; Michele R. Wilson; Matt Wasserman; Taj Jadavji; Maarten Postma; Marie-Claude Breton; Francois Peloquin; Stephanie R. Earnshaw; Cheryl L. McDade; Heather L Sings; Raymond A. Farkouh

Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"

Wilson, M. R., Wasserman, M., Jadavji, T., Postma, M., Breton, M.-C., Peloquin, F., Earnshaw, S. R., McDade, C., Sings, H. L., & Farkouh, R. (2018). Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada". Infectious Diseases and Therapy, 7(4), 539-543. https://doi.org/10.1007/s40121-018-0221-2

Copy citation